At a glance
ClinicalIndex Comparison Record- ✓Age 55 to 70 years
- ✓Alaska Native ethnicity
- ✕Immune compromising condition
- ✕Neurological disease
- ✕Immune suppressive medication or immunoglobulin within 6 months
- ✕Previous pneumococcal vaccination
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Native Elders
In Brief
A Phase 1 clinical trial evaluating PCV7 + PPV23, 2 months and PCV7 + PPV23, 6 months for Pneumococcal Infections. Completed, enrolled 86 participants across 1 site.
Detailed Summary
To test the hypothesis that immune responses to 23-valent pneumococcal polysaccharide vaccine (PPV-23) could be improved in Alaska Native elders by immune priming with 7-valent pneumococcal conjugate vaccine (PCV-7), we assessed post-vaccination immune responses among Natives aged 55 years and older who were randomized into three arms: (1) one dose of PPV-23 according to current state and ACIP recommendations; (2) one dose of PCV-7 followed two months later with a dose of PPV-23; and (3) one dose of PCV-7 followed six months later with a dose of PPV-23.